- Home
- LEU vs AUTL Comparison
LEU vs AUTL Comparison
Compare LEU & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- AUTL
- Stock Information
- Founded
- LEU 1998
- AUTL 2014
- Country
- LEU United States
- AUTL United Kingdom
- Employees
- LEU N/A
- AUTL N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEU Industrials
- AUTL Health Care
- Exchange
- LEU Nasdaq
- AUTL Nasdaq
- Market Cap
- LEU 4.2B
- AUTL 625.4M
- IPO Year
- LEU 1998
- AUTL 2018
- Fundamental
- Price
- LEU $261.12
- AUTL $1.33
- Analyst Decision
- LEU Buy
- AUTL Strong Buy
- Analyst Count
- LEU 11
- AUTL 5
- Target Price
- LEU $194.80
- AUTL $9.12
- AVG Volume (30 Days)
- LEU 1.2M
- AUTL 4.4M
- Earning Date
- LEU 10-27-2025
- AUTL 11-11-2025
- Dividend Yield
- LEU N/A
- AUTL N/A
- EPS Growth
- LEU 10.12
- AUTL N/A
- EPS
- LEU 6.16
- AUTL N/A
- Revenue
- LEU $436,900,000.00
- AUTL $29,934,000.00
- Revenue This Year
- LEU $3.52
- AUTL $641.63
- Revenue Next Year
- LEU $8.01
- AUTL $109.21
- P/E Ratio
- LEU $37.34
- AUTL N/A
- Revenue Growth
- LEU 12.72
- AUTL 185.17
- 52 Week Low
- LEU $39.19
- AUTL $1.11
- 52 Week High
- LEU $264.90
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- LEU 69.82
- AUTL 29.57
- Support Level
- LEU $221.23
- AUTL $1.26
- Resistance Level
- LEU $243.80
- AUTL $1.46
- Average True Range (ATR)
- LEU 15.96
- AUTL 0.09
- MACD
- LEU 5.22
- AUTL 0.01
- Stochastic Oscillator
- LEU 99.24
- AUTL 18.29
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.